{"prompt": "['4', 'DOCUMENT REVISION HISTORY', 'Date', 'Summary of changes', 'Version A', '06FEB2018', 'Original document', 'Version B', '02APR2018', 'Clarification on Exclusion Criteria #15. Removing screening', '- -14 days and replacing with -15 days window. Clarification to', 'Exclusion #13 to add \"chronic\" use of systemic corticosteroids.', 'Removal of \"Simultaneous bilateral testing can be done\" from', 'SPP and ABI sections. Clarification of Screening Visit Window.', 'Change to foot measurement process to allow measuring from', 'floor. Addition of Venous Insufficiency Classification Scale.', 'Version C', '17JUL2018', 'Two-month open label extension period updated to an 8-month', 'open label extension period. Additional phone calls and clinic', 'visits added to visit schedule.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['5', 'Study Synopsis', 'Study Title', 'A Multi-Center, Double-Blind, Sham-Controlled,', 'Randomized Trial of Dual Field PEMF Therapy [Provant', 'Therapy System] in Lower Extremity Painful Diabetic', 'Distal Symmetric Peripheral Neuropathy (DSPN) (The', 'RELIEF Trial)', 'Protocol Number', 'RBI.2017.002', 'Name of Study Device', 'PROVANTR Therapy System', 'Phase of Development', 'III', 'Objective', 'To demonstrate the analgesic efficacy of PEMF treatment', 'compared to sham treatment in patients with painful diabetic', 'distal symmetric peripheral neuropathy (DSPN) when treatment', 'is administered 30 minutes twice daily through a 120-day period', '(4 months) (Part A). An 8-month open-label active treatment', 'extension period is included to collect longer-term data on pain,', 'medication use, quality of life and safety (Part B).', 'Study Design', 'Part A of this trial is a multi-center, prospective, double-blinded,', 'sham-controlled, randomized clinical trial conducted on subjects', 'with painful diabetic distal symmetric peripheral neuropathy.', 'Part B of this trial is an 8-month single-arm, open-label, active', 'treatment extension period upon completion of Part A.', 'Eligible subjects will include those between 22 and 80 years of', 'age with documented Type 1 or Type 2 diabetes having persistent', 'pain related to diabetic neuropathy in the lower extremities,', 'despite previous treatment(s). Subjects will be assessed with the', 'Toronto Clinical Neuropathy Score at screening, to evaluate the', 'severity of peripheral neuropathy for inclusion.', 'Eligible subjects will be entered into a 14-day ePRO diary run-in', 'period to collect average baseline pain scores related to their', 'diabetic neuropathy in the lower extremities, diary compliance,', 'and analgesic consumption (maintenance and prn prescribed', 'peripheral neuropathic pain medication pill counts). Subjects will', 'collect electronic patient-reported outcome (ePRO) data each', 'morning around the same time during the run-in period. Only', 'those subjects having a mean pain intensity in the lower', 'extremities of>4 and <9 on an 11-point numeric pain rating scale', '(NPRS) and a diary compliance score of > 70% during the 14-', 'day run-in period will be eligible.', 'Subjects will return to the clinic at Baseline (Day 0) for review', 'of eligibility, diary compliance, average baseline diabetic', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['6', 'neuropathic pain score of >4 and <9 (calculated as the average of', 'the last 7 days preceding the enrollment visit), and review of', 'stable analgesic pain consumption profile during the 14-day run-', 'in period. Qualified subjects based on diary compliance and', 'average pain score will be randomized 1:1 (active: sham) and will', 'be instructed to self-treat twice daily (morning and evening; 8am', '2 hours and 8pm 2 hours) for 120 days. Subjects will record', 'electronic patient-reported outcome (ePRO) data following each', 'morning treatment for 120 days. Subjects consenting to distal', 'thigh and distal leg skin biopsies during the Screening visit will', 'have biopsies collected and sent to the central laboratory for', 'assessment. All subjects will have a baseline Skin Perfusion', 'Pressure (SPP), Sural Nerve Conduction Studies (NCS),', 'Quantitative Sensory Testing (QST), and will complete the Work', 'Productivity and Activity Impairment Questionnaire (WPAIQ),', 'and NeuroQoL.', 'Subjects will receive a telephone call at Day 7 to ensure', 'compliance to treatment and diary completion, provide follow-', 'up information on the biopsy sites (if applicable), complete a', 'blinding assessment as well as be assessed for safety and', 'concomitant medication changes.', 'At Month 1 subjects will return to the clinic for evaluation of', 'safety, concomitant medication changes, review device usage', '(reports will be supplied to the site) and ePRO diary completion,', 'and Patient Global Impression (PGI). Treatment satisfaction will', 'also be assessed.', 'At Month 2 subjects will return to the clinic for evaluation of', 'safety, concomitant medication changes, treatment satisfaction,', 'review of device usage (reports will be supplied to the site) and', 'ePRO diary completion, quality of life outcomes (WPAIQ and', 'NeuroQoL), Patient Global Impression (PGI), and interim visit', 'measurements of SPP.', 'At Month 3, subjects will return to the clinic for evaluation of', 'safety, concomitant medication changes, review device usage', '(reports will be supplied to the site) and ePRO diary completion,', 'and Patient Global Impression (PGI). Treatment satisfaction will', 'also be assessed.', 'At Month 4 (end of Part A / start of Part B), subjects will return', 'to the clinic for evaluation of safety, treatment satisfaction,', 'review of device usage (reports will be supplied to the site),', 'HbA1c, concomitant medication changes, weight, quality of life', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}